Glucose intolerance and hypoadiponectinemia are already present in lean patients with chronic hepatitis C infected with genotype non-3 viruses
- 1 August 2007
- journal article
- research article
- Published by Wolters Kluwer Health in European Journal of Gastroenterology & Hepatology
- Vol. 19 (8) , 671-677
- https://doi.org/10.1097/meg.0b013e3281532b9a
Abstract
Objectives Steatosis and metabolic abnormalities seem to be frequent and deleterious in chronic hepatitis C. Changes in glucose homeostasis and in adiponectin levels, an adipokine with anti-inflammatory and insulin-sensitive properties, were evaluated in patients with chronic hepatitis C according to steatosis, liver fibrosis and body mass index. Methods Seventy-three patients with chronic hepatitis C (40 men, 33 women) infected with genotypes non-3 and 22 healthy controls (11 men and 11 women) were included in the study and all had a biochemical evaluation, including metabolic parameters, adiponectin measurement, and a liver biopsy. Insulin sensitivity was assessed with the HOMA 1-IR insulin resistance model. Results Steatosis was found in 65.7% of the patients and significant fibrosis (METAVIR F2–F4) was present in 28.7%. The presence of steatosis could only be predicted by fibrosis, whereas significant fibrosis could be predicted by steatosis and age. Adiponectin levels were significantly decreased (−32%) with the severity of the steatosis. Although overweight chronic hepatitis C patients (body mass index≥25 kg/m2) had insulin resistance and hypoadiponectinemia, lean chronic hepatitis C patients (body mass index2) had already significantly higher glycemia and lower adiponectin levels than in controls. Conclusions This study confirms the high incidence of steatosis in patients infected by hepatitis C virus genotypes non-3, well linked to the development of fibrosis and metabolic abnormalities. Importantly, the present findings put emphasis on the early development of these metabolic abnormalities as they were already found in lean patients with chronic hepatitis C. The direct implication of hepatitis C virus is thus further stressed in the development of steatosis and insulin resistance, with or without involvement of host factors.Keywords
This publication has 36 references indexed in Scilit:
- Steatosis: Co-factor in Other Liver Diseases *Hepatology, 2005
- Adiponectin – journey from an adipocyte secretory protein to biomarker of the metabolic syndromeJournal of Internal Medicine, 2005
- Beyond insulin resistance in NASH: TNF-α or adiponectin?Hepatology, 2004
- The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patientsJournal of Hepatology, 2004
- In overweight patients with chronic hepatitis C, circulating insulin is associated with hepatic fibrosis: implications for therapyJournal of Hepatology, 2003
- Worsening of steatosis and fibrosis progression in hepatitis CGut, 2003
- Steatosis in chronic hepatitis C: Relative contributions of obesity, diabetes mellitus, and alcoholHepatology, 2002
- Genotype‐specific mechanisms for hepatic steatosis in chronic hepatitis C infectionJournal of Gastroenterology and Hepatology, 2002
- Steatosis Accelerates the Progression of Liver Damage of Chronic Hepatitis C Patients and Correlates With Specific Hcv Genotype and Visceral ObesityHepatology, 2001
- Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3Journal of Hepatology, 2000